Business
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).CTX-8371 was generally well tolerated with no observed dose limiting toxici
About this update from Compass Therapeutics, Inc.
[{"type":"image","alt":"Compass Therapeutics","displaySize":"","headline":null,"caption":"Compass Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e0q.NZaC1.yytJcmIgZeZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOQ--/https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b","width":300,"height":78},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/e0q.NZaC1.yytJcmIgZeZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOQ--/https://media.zenfs.com/en/globenewswire.com/24acefcca952f8de468624053ca6bd5b","width":300,"height":78}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with advanced malignancies resistant to prior immune checkpoint inhibitors.","length":267,"tagName":"p"}]},{"val":[{"type":"text","content":"Deep and durable responses were observed in patients with triple-negative breast cancer (TNBC), Hodgkin lymphoma (HL), and non-small cell lung cancer (NSCLC).","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"CTX-8371 was generally well tolerated with no observed dose limiting toxicities (DLTs).","length":87,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":512,"olType":false},{"type":"text","content":"BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced a poster presentation of data from the Phase 1 study of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies treated in the post-checkpoint inhibitor setting will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.","length":582,"tagName":"p"},{"type":"text","content":"“We are pleased to share the initial clinical data from the dose escalation portion of our ongoing Phase 1 study of CTX-8371 in patients with advanced malignancies treated in the post-chec...